8-K: CG Oncology's Bladder Cancer Drug Shows Strong 24-Month Durability

CG Oncology announced updated Phase 3 data for cretostimogene, demonstrating robust 24-month complete response and durability in high-risk BCG-unresponsive NMIBC patients.

Summary

• Updated data from Cohort C of the BOND-003 Phase 3 clinical trial for cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients was reported.
• An additional 12 patients achieved complete response (CR) at 24 months.
• The 24-month complete response landmark rate was 41.8% (46 out of 110 patients).
• The study reported a 75.5% CR at any time.
• Estimated 12-month duration of response (DOR) rate is 64.1%, and 24-month DOR rate is 58.3%.
• Median DOR is 28 months and is ongoing.
• 96.6% of patients were free from progression to muscle invasive disease at 24 months.
• Cretostimogene was generally well-tolerated with no Grade 3 or greater treatment-related adverse events (TRAEs) or deaths reported.
• Median resolution time for TRAEs of any grade was one day.
• No treatment-related discontinuation of cretostimogene was observed, with 97.3% of patients completing all expected treatments.
• The most common TRAEs (≥10%) included bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria.
• The study included 110 efficacy-evaluable, highly pretreated patients, making it the largest study in this population to date, with patients receiving a median of 12 prior BCG doses.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong and positive clinical trial data for cretostimogene, highlighting 'unprecedented' durability and excellent tolerability in a high-need patient population. The clear path to BLA submission in Q4 2025 further reinforces a highly favorable outlook.

Positives

• Robust 24-month complete response rate of 41.8% in a challenging patient population (high-risk BCG-unresponsive NMIBC).
• High durability of response, with 90% of 12-month responders remaining disease-free at 24 months, described as 'unprecedented' by a leading urologic oncologist.
• Strong prevention of disease progression, with 96.6% of patients free from progression to muscle invasive disease at 24 months.
• Excellent safety profile with no Grade 3 or greater treatment-related adverse events or deaths.
• High patient adherence and compliance, with 97.3% completing all expected treatments and no treatment-related discontinuations.
• Median duration of response of 28 months and ongoing, indicating sustained efficacy.
• The data reaffirms 'best-in-disease durability' previously announced.

Risks

• Additional patient data related to cretostimogene that continues to become available may be inconsistent with the data produced as of the data cutoff.
• Further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof.
• Results from earlier clinical trials and preclinical studies are not necessarily predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and/or commercialization.
• Potential delays in the commencement, enrollment, and completion of clinical trials.
• Competitive developments with respect to current and other investigational NMIBC treatments may adversely affect the commercial opportunity of cretostimogene.
• Other risks described in SEC filings, including under the heading Risk Factors in the annual report on Form 10-K and quarterly report on Form 10-Q.

Future Outlook

The company believes cretostimogene has the potential to offer significant therapeutic benefits for high-risk and intermediate-risk NMIBC patients, demonstrating best-in-disease durability and tolerability, and meaningfully improving patient outcomes. Management is eager to bring this innovative treatment to a broad range of NMIBC patients and is preparing to initiate its Biologics License Application (BLA) submission in the fourth quarter of 2025.

Management Comments

• Trinity J. Bivalacqua, MD, PhD, Urologic Oncology at Penn Medicine, stated: 'I remain very encouraged that if approved, cretostimogene will represent an important, bladder-sparing advancement in the management of high risk non-muscle invasive bladder cancer in patients who have disease that is unresponsive to BCG.'
• Dr. Bivalacqua also noted: 'The latest data from the BOND-003 Cohort C study demonstrates that if a patient is a responder at 12 months, there is a 90 percent chance they will remain in response at 24 months. This is unprecedented in the high-risk, heavily pretreated NMIBC patient population and very meaningful for those battling this difficult disease.'
• Ambaw Bellete, President & Chief Operating Officer at CG Oncology, commented: 'The data from our Phase 3 BOND-003 Cohort C registrational trial underscores cretostimogenes potential to become a breakthrough backbone treatment for bladder cancer patients.'
• Mr. Bellete added: 'We are eager to bring this innovative treatment to a broad range of NMIBC patients, and we are making great strides towards that goal as we prepare to initiate our BLA submission for cretostimogene in our initial indication for the treatment of patients with HR NMIBC unresponsive to BCG in the fourth quarter of this year.'

Industry Context

The NMIBC market, particularly for BCG-unresponsive patients, represents a significant unmet medical need. Current treatment options often lead to cystectomy (bladder removal) due to recurrence or progression. Cretostimogene's demonstrated durability and tolerability, especially in heavily pretreated patients, positions it as a potentially transformative bladder-sparing therapeutic. Its 'best-in-disease' and 'unprecedented' claims suggest it could set a new standard for efficacy and safety in this challenging indication, potentially reducing the need for radical surgery.

Comparison to Industry Standards

• The 90% chance of 12-month responders remaining in response at 24 months is described as 'unprecedented in the high-risk, heavily pretreated NMIBC patient population' by Dr. Trinity J. Bivalacqua, indicating superior durability compared to existing therapies.
• The company reaffirms 'best-in-disease durability' for cretostimogene monotherapy, suggesting it outperforms other treatments for high-risk BCG-unresponsive NMIBC.
• Cretostimogene's safety profile, with no Grade 3 or greater TRAEs and high patient adherence, offers distinct advantages over existing therapies which may have more severe side effects or lower compliance rates, particularly in a patient population that has often failed multiple prior treatments including BCG.

Stakeholder Impact

• **Shareholders:** Highly positive clinical data and a clear regulatory path are likely to significantly boost investor confidence and potentially the company's stock price.
• **Patients:** Offers a promising, bladder-sparing therapeutic option with high durability and excellent tolerability for high-risk BCG-unresponsive NMIBC, addressing a critical unmet medical need.
• **Healthcare Providers:** Provides a new, effective, and well-tolerated treatment tool for managing a challenging bladder cancer patient population, potentially reducing the need for radical surgery.
• **Regulatory Authorities:** The strong data supports the potential for regulatory approval, contributing to the availability of new treatments for cancer.

Next Steps

• Presentation of updated BOND-003 Cohort C data by Trinity J. Bivalacqua, MD, PhD, at the New England Section of the American Urological Association's 94th annual meeting on September 6, 2025.
• Initiation of Biologics License Application (BLA) submission for cretostimogene in high-risk BCG-unresponsive NMIBC in the fourth quarter of 2025.
• Continued clinical development for cretostimogene in other NMIBC indications (PIVOT-006 for intermediate-risk NMIBC, CORE-008 for high-risk NMIBC).
• Ongoing Expanded Access Program for cretostimogene in North America for eligible BCG-unresponsive patients.

Key Dates

Recommendation

The updated Phase 3 data for cretostimogene demonstrates exceptional durability and tolerability in high-risk BCG-unresponsive NMIBC, a patient population with limited effective options. The 'unprecedented' nature of the results, coupled with a clear timeline for BLA submission in Q4 2025, significantly de-risks the asset and points to a high probability of market approval and commercial success. This strong clinical performance and regulatory progress make CGON a compelling investment opportunity.

Keywords

CG Oncology, CGON, cretostimogene, bladder cancer, NMIBC, non-muscle invasive bladder cancer, BCG-unresponsive, BOND-003, Phase 3 clinical trial, complete response, durability of response, oncolytic immunotherapy, biopharmaceutical, oncology, clinical data, FDA approval, BLA submission